NEWSOfficial Launch of the ReSViNET Foundation
ZEIST, THE NETHERLANDS, 15 May 2018 – Today, we proudly announce the Official Launch of the ReSViNET Foundation as a registered not-for-profit entity under Dutch law. After 4 years of building and shaping the network and months of preparation, the ReSViNET Foundation has officially been founded.
As a foundation ReSViNET is now a financially and otherwise independent regulated entity which represents a major milestone for the entire ReSViNET project. Since the inception of ReSViNET network in 2014, we have continuously been working to fulfil our Vision and Mission: to decrease the global burden of RSV infection through the advancement of research; providing scientific input; involvement in clinical trials; and organising conferences and offering platforms to share the latest developments and reports on groundbreaking studies and in this way helping to move the field forward. We are exceptionally proud to be the first official Respiratory Syncytial Virus (RSV) foundation and aim to foster global collaboration among ... Advances in knowledge of the structural biology of the RSV surface fusion (F) glycoprotein#RSV #ReSViNET Advances in knowledge of the structural biology of the RSV surface fusion (F) glycoprotein have revolutionized RSV vaccine development by providing a new target for preventive interventions. It is explained in this video, which was made by Djonie Jacobsen; Nienke Mombarg and Charlotte Wiersma, students from De Streek school in Ede, The Netherlands in April 2018.
ReSViNET scale APP for pediatric respiratory assessment is now available
|
Subcutaneous treatment with diabetes drug liraglutide (Victoza®) is effective treatment of RSV infection
Melissa H. Bloodworth, Ph.D., Mark Rusznak, Connor C. Pfister, Jian Zhang, M.S., Lisa Bastarache, Ph.D., Sandra Alvarez Calvillo, B.S., James D. Chappell, M.D., Ph.D., Kelli L. Boyd, D.V.M., Ph.D., Shinji Toki, Ph.D., Dawn C. Newcomb, Ph.D., Matthew T. Stier, B.S., Weisong Zhou, Ph.D., Kasia Goleniewska, M.S., Martin L. Moore, Ph.D., Tina V. Hartert, M.D., M.P.H., Kevin D. Niswender, M.D., Ph.D., R. Stokes Peebles, Jr., M.D. The glucagon-like peptide(GLP)-1 receptor agonist liraglutide has the potential to be an effective treatment of RSV bronchiolitis. This is the conclusion from a mouse study from researchers from the Vanderbilt University (Nashville, TN) and Emory (Atlanta, GA). Mucus production is a hallmark of severe RSV bronchiolitis. Mucus production is mediated by the production of Th2 cytokines, in particular IL-13.To date, no treatment has proven to prevent mucus production during RSV infection. Liraglutide is a registered and commercially available diabetes GLP1-R agonist to suppress glucagon secretion. As it was known to be immunosuppressive, this study aimed to assess the drug’s potential as an RSV therapeutic. Liraglutide treatment decreased mucus production, airway hyperresponsiveness and lung pathology without affecting viral replication. This favorable outcome coincided with decreased IL-13 production and type 2 innate lymphoid cells (ILC) in the airways. The relevance for human RSV infection was supported by a SNP in the THADA gene which is known to define the beta-cell response to GLP-1. This study reveals a novel therapeutic pathway to improve the outcome of patients with RSV infection. In collaboration with RESCEU 
ReSViNET BROCHURE
| ||||
about REsvinet
RSV (Respiratory Syncytial Virus) infection is the second most important cause of death during infancy, especially in developing countries. RSV infection has also been linked to an increased risk in the development of chronic airway disease in later life. Therefore, research on RSV is crucial.
In order to improve research on RSV, ReSViNET (Respiratory Syncytial Virus Network) has been established. In this network, expertise and leadership are combined in order to decrease the global burden of RSV. It is our goal to improve knowledge of RSV epidemiology and to develop safe and effective therapeutic and preventive interventions.
In order to improve research on RSV, ReSViNET (Respiratory Syncytial Virus Network) has been established. In this network, expertise and leadership are combined in order to decrease the global burden of RSV. It is our goal to improve knowledge of RSV epidemiology and to develop safe and effective therapeutic and preventive interventions.
